Arq. Bras. Cardiol. 2021; 117(6): 1217-1218

Safety Margin for Plasma Hyperviscosity in Cardiovascular Disease Patients after COVID-19 Vaccination for Thrombosis Prevention

Rujittika Mungmunpuntipantip ORCID logo , Viroj Wiwanitkit

DOI: 10.36660/abc.20210555

Dear Editor,

We read the article entitled “Vaccinating Patients with Heart Disease Against COVID-19: The Reasons for Priority” with great interest. COVID-19 vaccination is accepted as the best way for preventing the disease, but data on its safety are still warranted. An important problem found after COVID-19 vaccination is the rheological change causing intravascular clotting and thrombotic complications. Changes in blood viscosity after COVID-19 vaccination have been confirmed. A vaccine can induced rapid production of antibody, which is a protein that can increase plasma viscosity by an estimated 2.4 centipoise (cP) from normal values in healthy person., The problem might occur if changes in plasma viscosity reach levels above 5 cP, considered a hyperviscosity state.

[…]

Safety Margin for Plasma Hyperviscosity in Cardiovascular Disease Patients after COVID-19 Vaccination for Thrombosis Prevention

Comments

Skip to content